{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:16:27Z","timestamp":1771928187553,"version":"3.50.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delayed pressure urticaria (DPU) is a disabling chronic inducible urticaria characterized by delayed painful swelling after sustained pressure. Evidence-based therapeutic options remain limited, and omalizumab is frequently used off-label in antihistamine-refractory cases despite scarce prospective DPU-specific data with objective provocation testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a prospective, single-center, open-label cohort, adults with dermographometer-confirmed DPU refractory to licensed or high-dose second-generation H1-antihistamines received omalizumab 300 mg subcutaneously every 4 weeks. Patients were contacted daily during the first week after the initial dose and deliberately exposed to their typical pressure triggers to define time to complete symptom control. Baseline clinico-demographic characteristics, laboratory parameters, atopic status and comorbidities were recorded, and potential predictors of time to response were explored by univariate regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-two patients were included (61.9% female; mean age at diagnosis 46.0 \u00b1 14.0 years). Aeroallergen sensitization was present in 52.4% and clinically documented allergic disease in 26.2%; autoimmune thyroid disease was recorded in 33.3%. The DPU phenotype frequently involved soles and\/or palms (54.8%), and angioedema (28.6%) and systemic symptoms (26.2%) were common. After the first omalizumab dose, 41\/42 patients (97.6%) achieved complete symptom control within 96 hours (median 24 hours); 57.1% responded within 24 hours and 83.3% within 48 hours. One patient achieved only partial control. No serious adverse events or need for rescue systemic corticosteroids were observed. Time to response was not associated with sex, age, baseline total IgE, aeroallergen sensitization, atopic background, or autoimmune thyroid disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In dermographometer-confirmed, antihistamine-refractory DPU, omalizumab was associated with a rapid clinical remission in almost all patients, typically within 24\u201348 hours, independent of baseline IgE and common comorbidities. Standardized pressure provocation testing provides objective confirmation of DPU and a pragmatic approach for diagnosis and real-world monitoring of therapeutic response in DPU. Given the open-label, uncontrolled design, these findings should be confirmed in larger multicenter controlled studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1768128","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T06:41:15Z","timestamp":1769668875000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"George N.","family":"Konstantinou","sequence":"first","affiliation":[{"name":"Department of Allergy and Clinical Immunology, 424 General Military Training Hospital","place":["Thessaloniki, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indrashis","family":"Podder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, College of Medicine and Sagore Dutta Hospital","place":["Kolkata, West Bengal, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.iac.2004.01.006","article-title":"Delayed pressure urticaria","volume":"24","author":"Lawlor","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(88)70137-1","article-title":"Delayed pressure urticaria. Clinical features, laboratory investigations, and response to therapy of 44 patients","volume":"18","author":"Dover","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(82)90022-7","article-title":"Delayed pressure urticaria","volume":"70","author":"Sussman","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70273-V","article-title":"Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria","volume":"29","author":"Barlow","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/all.12884","article-title":"The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI\/GA(2) LEN\/EDF\/UNEV consensus recommendations 2016 update and revision","volume":"71","author":"Magerl","year":"2016","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1989.tb04167.x","article-title":"Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine","volume":"120","author":"Lawlor","year":"1989","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.jaip.2020.03.004","article-title":"Delayed pressure urticaria: A systematic review of treatment options","volume":"8","author":"Kulthanan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/milmed\/usae333","article-title":"Delayed pressure urticaria associated with altitude chamber training responsive to cyclosporine and omalizumab","volume":"189","author":"Alix","year":"2024","journal-title":"Mil Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2025.46.250031","article-title":"Delayed pressure urticaria successfully treated with omalizumab: A tertiary-level health-care center experience","volume":"46","author":"Cakmak","year":"2025","journal-title":"Allergy Asthma Proc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02188.x","article-title":"Efficacy of omalizumab in delayed pressure urticaria: a case report","volume":"65","author":"Bindslev-Jensen","year":"2010","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.07.016","article-title":"Rapid response to omalizumab in 3 cases of delayed pressure urticaria","volume":"5","author":"Quintero","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000524887","article-title":"Delayed pressure urticaria: clinical and diagnostic features and response to omalizumab","volume":"183","author":"Veleiro-P\u00e9rez","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1016\/j.jaip.2023.09.002","article-title":"Autoimmune diseases and low baseline IgE in chronic spontaneous urticaria: A clinical and therapeutic prospective analysis in real-life clinical practice","volume":"11","author":"Pesqu\u00e9","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.10.003","article-title":"Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review","volume":"16","author":"Kolkhir","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s001050050461","article-title":"Epidemiologie und Klinik der K\u00e4lteurtikaria [Epidemiology and clinical aspects of cold urticaria","volume":"47","author":"M\u00f6ller","year":"1996","journal-title":"Hautarzt"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1159\/000535290","article-title":"A case-control study comparing the general characteristics of patients with symptomatic dermographism and chronic spontaneous urticaria: is atopy a risk factor for symptomatic dermographism","volume":"185","author":"Cakmak","year":"2024","journal-title":"Int Arch Allergy Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1071\/SH22029","article-title":"Delayed pressure urticaria manifesting as dyspareunia - is it that uncommon","volume":"19","author":"Konstantinou","year":"2022","journal-title":"Sex Health"},{"key":"B21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.12932\/AP-130825-2133","article-title":"Pathophysiological insights into delayed pressure urticaria: A comprehensive review","volume":"43","author":"Kulthanan","year":"2025","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality of life","volume":"136","author":"O\u2019Donnell","year":"1997","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02767.x","article-title":"The extent and nature of disability in different urticarial conditions","volume":"140","author":"Poon","year":"1999","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.07.018","article-title":"Omalizumab in the treatment of chronic inducible urticaria","volume":"108","author":"Chicharro","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015623795","article-title":"Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature","volume":"29","author":"Kasperska-Zajac","year":"2016","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.abd.2024.06.008","article-title":"Successful Omalizumab treatment in delayed pressure urticaria as confirmed by stimulation test","volume":"100","author":"Ariasi","year":"2025","journal-title":"Bras Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.03.007","article-title":"How to approach chronic inducible urticaria","volume":"6","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2021.13.4.545","article-title":"Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria","volume":"13","author":"Kolkhir","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaip.2022.11.006","article-title":"Urticaria and angioedema: understanding complex pathomechanisms to facilitate patient communication, disease management, and future treatment","volume":"11","author":"Konstantinou","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03256.x","article-title":"Pathogenesis of chronic urticaria","volume":"39","author":"Kaplan","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12693","article-title":"Omalizumab may not inhibit mast cell and basophil activation in vitro","volume":"29","author":"Gericke","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70506-3","article-title":"Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria","volume":"103","author":"Hermes","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2340\/0001555567438441","article-title":"Delayed pressure urticaria syndrome: a clinical expression of interleukin 1","volume":"67","author":"Shelley","year":"1987","journal-title":"Acta Derm Venereol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06677.x","article-title":"Bullous delayed pressure urticaria: pathogenic role for eosinophilic granulocytes","volume":"153","author":"Kerstan","year":"2005","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb06916.x","article-title":"Immunohistological comparison of granulated cell proteins in induced immediate urticarial dermographism and delayed pressure urticaria lesions","volume":"133","author":"McEvoy","year":"1995","journal-title":"Br J Dermatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13644","article-title":"Delayed bullous pressure urticaria: the puzzling role of eosinophils","volume":"16","author":"Weins","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.12.658","article-title":"Successful treatment of delayed pressure urticaria with anti-TNF-alpha","volume":"119","author":"Magerl","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune chronic spontaneous urticaria detection with IgG anti-TPO and total ige","volume":"9","author":"Kolkhir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.waojou.2025.101116","article-title":"Association between circulating thyroperoxidase (TPO), anti-TPO IgE, anti-TPO IgG, and different clinical outcomes in chronic urticaria: A hypothesis-generating study","volume":"18","author":"Lopez","year":"2025","journal-title":"World Allergy Organ J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.03.012","article-title":"Sexual intercourse as a trigger of inducible urticaria","volume":"122","author":"Geller","year":"2019","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1768128\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:25:24Z","timestamp":1771925124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1768128\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2026.1768128"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1768128","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1768128"}}